

GRAHAM JONES, PHD



Head of Research and Innovation,  
Connected Health Group, Novartis AG

- Executive leader in translational drug and biotech research and product innovation
- Prof. of Medicine, Tufts School of Medicine; Prof., Chair & Provost, Northeastern University
- PhD Imperial College London; DSc University of Liverpool; NATO Fellow, Harvard University

*“The ability to predict, monitor and guide health interventions through a combination of passive monitoring and active patient engagement is very promising.”*

Graham Jones is an executive and technical leader in pharmaceutical and biotechnology product development and innovation. He is currently the Head of Research and Innovation, Connected Health Group for Novartis AG.

He was recruited to Novartis from Tufts University Medical Center, where he was a Professor of Medicine and Director of Translational Research. Prior to that, Dr. Jones was Professor, Chair and Vice Provost at Northeastern University, where he oversaw technology transfer, commercialization and technology spinouts and directed drug development research programs. Dr. Jones holds a PhD from Imperial College London, was a NATO Fellow at Harvard University, and was awarded a DSc from the University of Liverpool for career contributions to medicinal chemistry.

*What inspired you to professionally focus on digital health?*

It represents a logical evolution of post-OMIC healthcare. Emerging laboratory technology and the forefront of biological study have begun to amass large reservoirs of data, newly referred to as “-omics” – *genomics, transcriptomics, proteomics, metabolomics*. Technological advances in sensing and monitoring devices coupled with availability of archive quality patient datasets have the near term potential to transform personalized medicine across the wellness-illness continuum.

*What do you find most interesting/promising about Smart Medicine tools and technologies?*

The ability to predict, monitor and guide health interventions through a combination of passive monitoring and active patient engagement.

*Why will the healthcare ecosystem embrace Smart Medicines as a digital solution?*

A combination of health economic benefit and high patient adherence and persistence levels will propel the deployment of digital solutions.